肝细胞癌等待肝移植期间立体定向体部放疗的前瞻性研究
本研究前瞻性纳入接受SBRT桥接治疗的HCC患者,并与回顾性TACE或HIFU队列比较。SBRT组1年肿瘤控制率显著高于TACE和HIFU,等待期退出累积发生率更低,围手术期毒性相似,移植后病理完全缓解率更高。SBRT安全,可作为传统桥接治疗的替代选择。
要点
- SBRT桥接治疗1年肿瘤控制率显著优于TACE和HIFU。
- SBRT降低等待期退出风险,且不增加围手术期毒性。
- SBRT后移植病理完全缓解率更高,移植后生存无差异。
核心结论
- SBRT作为肝移植桥接治疗安全,肿瘤控制率显著更高,降低等待期退出风险,应作为传统桥接治疗的替代选择。
研究设计与样本
- 前瞻性纳入2015年7月起按标准化方案接受SBRT的患者,与2010年起接受TACE或HIFU的回顾性队列比较,共评估150例(SBRT 40例,TACE 59例,HIFU 51例)。
- 主要终点为桥接治疗后1年肿瘤控制率,次要终点包括退出累积发生率、毒性和移植后生存。
主要发现
- 1年肿瘤控制率SBRT为92.3%,TACE为43.5%,HIFU为33.3%(P=0.02)。
- 等待名单后1年和3年退出累积发生率SBRT为15.1%和23.3%,TACE为28.9%和45.8%(P=0.034),HIFU为33.3%和45.1%(P=0.032)。
- 1年和3年进展时间比例SBRT为10.8%和18.5%,TACE为45%和54.9%,HIFU为47.6%和62.8%(P<0.001)。
- 移植后病理完全缓解率SBRT为48.1%,TACE为25%,HIFU为17.9%(P=0.037)。
- 围手术期毒性相似,围手术期并发症及移植后患者生存和无复发生存率无差异。
关键数值与推荐
- 多因素分析中,肿瘤大小<3 cm、登记时甲胎蛋白<200 ng/mL、Child A级和SBRT显著降低退出风险。
临床怎么用
- 对于等待肝移植的HCC患者,SBRT可作为桥接治疗的有效替代选择,尤其适用于符合肿瘤大小<3 cm、AFP<200 ng/mL和Child A级的患者。
局限性
- SBRT组为前瞻性队列,而TACE和HIFU组为回顾性队列,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: There are no prospective data on stereotactic body radiation therapy (SBRT) as a bridge to liver transplantation for HCC. This study aimed to evaluate the efficacy and safety of SBRT as bridging therapy, with comparison with transarterial chemoembolization (TACE) and high-intensity focused ultrasound (HIFU). APPROACH AND RESULTS: Patients were prospectively enrolled for SBRT under a standardized protocol from July 2015 and compared with a retrospective cohort of patients who underwent TACE or HIFU from 2010. The primary endpoint was tumor control rate at 1 year after bridging therapy. Secondary endpoints included cumulative incidence of dropout, toxicity, and posttransplant survival. During the study period, 150 patients were evaluated (SBRT, n = 40; TACE, n = 59; HIFU, n = 51). The tumor control rate at 1 year was significantly higher after SBRT compared with TACE and HIFU (92.3%, 43.5%, and 33.3%, respectively; P = 0.02). With competing risk analysis, the cumulative incidence of dropout at 1 and 3 years after listing was lower after SBRT (15.1% and 23.3%) compared with TACE (28.9% and 45.8%; P = 0.034) and HIFU (33.3% and 45.1%; P = 0.032). Time-to-progression at 1 and 3 years was also superior after SBRT (10.8%, 18.5% in SBRT, 45%, 54.9% in TACE, and 47.6%, 62.8% in HIFU; P < 0.001). The periprocedural toxicity was similar, without any difference in perioperative complications and patient and recurrence-free survival rates after transplant. Pathological complete response was more frequent after SBRT compared with TACE and HIFU (48.1% vs. 25% vs. 17.9%, respectively; P = 0.037). In multivariable analysis, tumor size <3 cm, listing alpha-fetoprotein <200 ng/mL, Child A, and SBRT significantly reduced the risk of dropout. CONCLUSIONS: SBRT was safe, with a significantly higher tumor control rate, reduced the risk of waitlist dropout, and should be used as an alternative to conventional bridging therapies.
引用
- Wong TC, Lee VH, Law AL, et al. Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. Hepatology. 2021. PMID: 34091914. doi:10.1002/hep.31992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。